Research programme: psychiatric and neurological disorders therapies - Evotec AG

Drug Profile

Research programme: psychiatric and neurological disorders therapies - Evotec AG

Alternative Names: Psychiatric and neurological disorders therapies research programme - Evotec

Latest Information Update: 02 Apr 2014

Price : $50

At a glance

  • Originator Evotec AG
  • Class
  • Mechanism of Action Orexin receptor type 2 modulators; Phosphodiesterase 10A modulators; Serine racemase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Insomnia; Neurodegenerative disorders; Schizophrenia
  • Discontinued Drug abuse

Most Recent Events

  • 02 Apr 2014 No development reported - Preclinical for Schizophrenia in Germany (unspecified route)
  • 02 Apr 2014 No development reported - Preclinical for Neurodegenerative disorders in Germany (unspecified route)
  • 02 Apr 2014 No development reported - Preclinical for Insomnia in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top